Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 04/11/2013 Glass bioreactor filled with a red liquid.

    Biotechnology – driver of innovation in the pharmaceutical industry

    The biotech industry is the innovative driver for a pharmaceutical industry that, due to the shift from blockbluster products to personalised medicine, now depends on new concepts. The production of new drugs using genetic engineering relies on knowledge gained from genomics, proteomics and systems biology and creates new treatment strategies that combine therapy and diagnostics (i.e. companion diagnostics) to provide a specific individualised…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-driver-of-innovation-in-the-pharmaceutical-industry
  • Article - 30/09/2013 Person holding a vial with vaccine.

    CureVac GmbH: RNA-based vaccines and immunotherapies

    CureVac GmbH, a biopharmaceutical company based in Tübingen, develops immunotherapies for cancer along with prophylactic vaccines based on its proprietary messenger RNA (mRNA) technology platform. CureVac also uses RNA for developing adjuvants. Two clinical trials, a Phase I trial in non-small cell lung cancer (NSCLC) and a Phase IIb trial in prostate cancer, are currently underway to test the efficiency of mRNA-based drugs in treating cancer and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-gmbh-rna-based-vaccines-and-immunotherapies
  • Article - 22/07/2013 17864_de.jpg

    FESTO – tapping into the bioproduction market

    Festo AG Co. KG is a leading provider of factory automation and process automation. The company has been involved in and contributed to shaping the development of such automation solutions ever since its foundation in 1925. Festo markets electrical and pneumatic drive technology valves sensors and other automation components as well as complete control units. Moreover when industrial bioproduction involving living microorganisms was gaining in…

    https://www.gesundheitsindustrie-bw.de/en/article/news/festo-tapping-into-the-bioproduction-market
  • Article - 02/05/2013 19616_de.jpg

    Borderline products – products with medicinal property

    Borderline products are products that fall into categories somewhere in-between pharmaceuticals, foods and cosmetics. The number of such products sold over the Internet is increasing, and most of them are declared as dietary supplements. A Joint Expert Commission of the German Federal Office of Consumer Protection and Food Safety and the German Federal Institute for Drugs and Medical Devices has now been set up with the aim of shedding light onto…

    https://www.gesundheitsindustrie-bw.de/en/article/news/borderline-products-products-with-medicinal-property
  • Press release - 30/04/2013 19630_de.jpg

    Impressions from the 2013 BIO International Convention in Chicago

    A trade fair turns 20 and an industrial sector is coming of age. Where does BIO stand today? The number of exhibitors has slightly decreased the conference is characterised by general themes and trends and partnering has become the most important and indispensable part of the global event for biotechnology. What was once a gold rush atmosphere has given way to an experienced self-confidence about the economic importance of biotechnology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/impressions-from-the-2013-bio-international-convention-in-chicago
  • Press release - 29/04/2013 19637_de.jpg

    BIOBreakfast: exclusive networking in Chicago

    The annual Networking Breakfast was held at the Chicago Club on 23rd April 2013 on the occasion of the 2013 BIO International Convention the global event for biotechnology. As part of the event Heidelberg Technology Park HTP and the University Technology Park in Chicago unveiled an expanded partnering programme. Around 70 participants from 12 countries used the exclusive setting to make new international contacts renew old ones and exchange…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biobreakfast-exclusive-networking-in-chicago
  • Dossier - 15/04/2013 19496_de.jpg

    Bioactive plant foods – more than just filling

    The increasing demand for functional foods clearly shows that the role of food is no longer just to meet an essential need. Food that offers additional nutritional benefits is becoming increasingly important for example food that is able to prevent or treat diseases. This kind of food is therefore interesting for consumers the food industry and the healthcare sector alike. Products based on plant raw materials are particularly in demand due to…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/bioactive-plant-foods-more-than-just-filling
  • Article - 12/03/2013 19326_de.jpg

    Science to business – exit strategies for biotech companies

    The two directors of the consultancy firm LSCN Ltd. Dr. Alrik Koppenhöfer and Dr. Volker Ungermann explain the key issues involved in MA negotiations and licensing deals and how LSCN supports biotechnology companies and strategic investors in reaching their goals. Both managers agree that a good dose of realism is necessary.

    https://www.gesundheitsindustrie-bw.de/en/article/news/science-to-business-exit-strategies-for-biotech-companies
  • Article - 11/02/2013 19222_de.jpg

    Quality management: burden or opportunity?

    Companies are facing increasing demands. Globalisation and an increasingly quality-conscious market increase competition and pricing pressure. To remain globally competitive companies need a product and service quality that will satisfy the customer in the long term. Alexander Cansier managing director of OrgaConnect GmbH has specialised in the support of small and medium-sized companies in the life sciences pharmaceutical and medical technology…

    https://www.gesundheitsindustrie-bw.de/en/article/news/quality-management-burden-or-opportunity
  • Article - 04/02/2013 19110_de.jpg

    DKFZ-HIPO – the Heidelberg Center for Personalised Oncology

    The German Cancer Research Center (DKFZ) and the National Center for Tumour Diseases (NCT) have jointly initiated the Heidelberg Center for Personalised Oncology (HIPO) which provides cancer patients with high-throughput genetic and molecular analyses. In anticipation of the upcoming World Cancer Day on 4th February 2013, the potential of high-throughput genetic and molecular analyses in improving cancer therapy was presented at a workshop held…

    https://www.gesundheitsindustrie-bw.de/en/article/news/dkfz-hipo-the-heidelberg-center-for-personalised-oncology
  • Article - 04/02/2013 08265_de.jpg

    SYGNIS Pharma - the "new" one: development and commercialisation of molecular diagnostics products

    Heidelberg-based SYGNIS Pharma AG is to discontinue its therapeutic R&D projects targeting human nervous system diseases and will in future focus on the research and development of novel molecular biology technologies, including DNA amplification and sequencing as well as drug screening.

    https://www.gesundheitsindustrie-bw.de/en/article/news/sygnis-pharma-the-new-one-development-and-commercialisation-of-molecular-diagnostics-products
  • Article - 07/01/2013 19006_de.jpg

    HepaChip: a promising tool for assessing adverse drug effects

    Liver damage is one of the most common adverse drug effects. Since results obtained with animal experiments can only be transferred to the situation in humans to a limited extent, there is a need for cell-based systems that model human organ function as closely as possible. The new HepaChip, developed by researchers at the NMI in Reutlingen on the basis of human liver and endothelial cells is able to do just this.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hepachip-a-promising-tool-for-assessing-adverse-drug-effects
  • Article - 17/12/2012 18923_de.jpg

    Medicyte GmbH – gold standard for human cells

    Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicyte-gmbh-gold-standard-for-human-cells
  • Press release - 09/11/2012 Logo apogenix

    Apogenix’s Apocept™ for glioblastoma multiforme named one of “Top 10 Projects to Watch”

    Apogenix a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases announced that its lead product Apocept APG101 has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncologys Top 10 Projects To Watch.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-s-apocept-for-glioblastoma-multiforme-named-one-of-top-10-projects-to-watch
  • Press release - 08/10/2012 10529_de.jpg

    Affimed raises € 15.5 million in a Series D financing round

    Affimed Therapeutics AG the therapeutic TandAb antibody company announced the successful closing of a Series D financing round of 15.5 million on 8 October 2012. The proceeds from this transaction will be used to fund the clinical development of Affimeds therapeutic pipeline that consists of two TandAb products AFM11 and AFM13. Both candidates have unique properties as shown in preclinical studies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-raises-15-5-million-in-a-series-d-financing-round
  • Press release - 08/08/2012 Logo apogenix

    Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial

    The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
  • Press release - 01/08/2012 SYGNIS Pharma AG Logo

    Combination of businesses of SYGNIS and GENETRIX’ subsidiary X-Pol proposed

    SYGNIS Pharma AG and GENETRIX announced today, that the biotechnology companies SYGNIS and GENETRIX have signed a binding Term Sheet under which the companies propose to combine the GENETRIX’ DNA sequencing subsidiary X-Pol Biotech and SYGNIS. Goal is to develop and market X-Pol Biotech, S.L.’s DNA sequencing technologies and products.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/combination-of-businesses-of-sygnis-and-genetrix-subsidiary-x-pol-proposed
  • Article - 09/07/2012 The photo shows a number of Vetter Pharma's apprentices, bachelor’s, master’s and diploma graduates. Continuous growth has meant that Vetter Pharma has had to recruit increasing numbers of new staff.

    Bachelor’s and master’s graduates – what really counts is individual aptitude

    Ravensburg-based Vetter Pharma GmbH has been constantly growing over the last few years; the company took on 300 new staff in 2011 and plans to recruit 350 more in 2012. The company is desperately looking for qualified young people to help manage its growth. In what way does this impact on job opportunities for bachelor’s and master’s graduates? In the following interview, Christiane Priebe, Director of Human Resources at Vetter Pharma, talks…

    https://www.gesundheitsindustrie-bw.de/en/article/news/bachelor-s-and-master-s-graduates-what-really-counts-is-individual-aptitude
  • Article - 09/07/2012 Previously abundant in Europe, the number of noble crayfish has dramatically fallen due to a disease known as American crayfish plague.

    Crayfish chitin is an important raw material

    In his Konstanz-based Vegafood project office Dr. Peter May is focused on sustainable breeding of crayfish with the aim of advancing industrial scale chitin research. European crayfish shed their skin several times a year providing research institutions and chitin product manufacturers with access to crustacean carapaces.

    https://www.gesundheitsindustrie-bw.de/en/article/news/crayfish-chitin-is-an-important-raw-material
  • Article - 02/07/2012 The photo shows a CT image of pink and red human organs. The liver is shown in pink.

    Together against liver failure

    Medicines that are usually effective in treating diseases can sometimes be associated with severe adverse effects. This can occur when the liver which normally metabolizes drugs and renders them harmless becomes overburdened and even collapses completely. Prof. Dr. Jens Timmer from the University of Freiburg and Prof. Dr. Ursula Klingmüller from the German Cancer Research Center DKFZ in Heidelberg have joined forces in a huge European research…

    https://www.gesundheitsindustrie-bw.de/en/article/news/together-against-liver-failure
  • Article - 25/06/2012 17478_de.jpg

    Cannabidiol for the treatment of schizophrenic psychoses

    A hemp compound has been shown to increase the effect of the endogenous cannabinoid anandamide in the human brain, thus reducing the delusions associated with psychotic diseases. Studies carried out by Prof. Markus Leweke from the Central Institute of Mental Health in Mannheim involving patients with acute schizophrenic attacks show that the plant compound is better tolerated than currently approved antipsychotic drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cannabidiol-for-the-treatment-of-schizophrenic-psychoses
  • Press release - 30/05/2012 10344_de.jpg

    Valuable Discussions at the Third International DDI Workshop

    The organisation team of the Third International DDI (drug-drug interactions) Workshop has expressed great satisfaction with the course of the scientific meeting. The participants of the DDI Workshop commended the very high scientific level of the presentations and valuable and inspiring discussions of the different topics. Without a doubt, the DDI Workshop at Marbach Castle is a well established platform for the annual exchange between experts,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/valuable-discussions-at-the-third-international-ddi-workshop
  • Article - 29/05/2012 17307_de.jpg

    Intestinal bacteria and human gut types

    The type of bacteria that colonize the human gut does not just influence our digestion and well-being. Metagenome sequencing has provided an international consortium involving scientists from the European Molecular Biology Laboratory at the University Hospital of Heidelberg with evidence that certain individuals have different gut types with different types of bacteria. Such individuals not only differ in their predisposition to disease, but also…

    https://www.gesundheitsindustrie-bw.de/en/article/news/intestinal-bacteria-and-human-gut-types
  • Press release - 24/05/2012 17315_de.jpg

    Jiangsu Life Science and Technology Innovation Park

    The park is still under construction (first construction phase finished in autumn 2012). Located in Xianlin University Town, East of Nanjing Center, it is in the immediate neighborhood of the new campuses of Nanjing University, Nanjing Normal University, Nanjing University of Traditional Chinese Medicine and China Pharmaceutical University.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/jiangsu-life-science-and-technology-innovation-park
  • Press release - 04/05/2012

    Novaliq receives €3.9 million in further round of financing talks

    Novaliq GmbH, a drug delivery company focusing on difficult to dissolve substances for ophthalmic and dermatological applications, announced the conclusion of a round of financing talks resulting in €3.9 million.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novaliq-receives-3-9-million-in-further-round-of-financing-talks

Page 3 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search